Discussion
Switching to Nexviadyme (avalglucosidase alfa) may help stabilize declining walking ability in adults with late-onset Pompe disease whose symptoms worsen despite treatment with Myozyme (alglucosidase alfa), according to a real-world study from France. Researchers found that the group’s decline in walking ability halted during the first year…